The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Coronary interventions

Ten-year outcomes from a randomised comparison of zotarolimus-eluting and sirolimus-eluting stents: the SORT OUT III study

EuroIntervention 2019;15:e1022-e1024. DOI: 10.4244/EIJ-D-19-00503

1. Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark; 2. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 3. Department of Cardiology, Odense University Hospital, Odense, Denmark; 4. Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark


Previous studies have raised concerns about the possible increased risks of early stent thrombosis and target lesion revascularisation with the Endeavor® Sprint zotarolimus-eluting stent (ZES; Medtronic, Minneapolis, MN, USA) when compared with the CYPHER Select® Plus sirolimus-eluting stent (SES; Cordis, Johnson & Johnson, Warren, NJ, USA)1,2. As these differences appeared to diminish over time, a potential reversal of their safety profiles with prolonged follow-up was suggested1,2. The purpose of this study was to examine 10-year outcomes in patients who received ZES versus SES in the Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Intravascular lithotripsy in chronic total occlusion percutaneous coronary intervention